Labradors' overeating gene may explain human obesity risk, researchers say
The Brief
A new study from the University of Cambridge found that Labradors and humans share a key gene linked to obesity.
The DENND1B gene influences hunger signals in the brain, making those with the variant more prone to overeating.
Researchers say the findings shed light on how genetic risk contributes to obesity in humans.
LOS ANGELES - Scientists studying Labrador retrievers—a breed known for its insatiable appetite—have discovered a genetic link between obesity in dogs and humans.
The DENND1B gene, previously linked to obesity in people, was found to alter hunger signals in Labradors, making them more prone to overeating. Researchers at the University of Cambridge analyzed the genetics of 250 Labradors and found that dogs carrying this gene variant had about 8% more body fat than those without it.
Dr. Eleanor Raffan, the study's lead researcher, emphasized that genetic predisposition plays a significant role in weight gain.
"Owners of slim dogs are not morally superior. The same is true of slim people," Raffan said. "If you have a high genetic risk of obesity, then when there's lots of food available, you're prone to overeating and gaining weight unless you put a huge effort into not doing so."
By the numbers
Obesity in dogs and humans is influenced by both genetic and environmental factors. Just as humans with high genetic risk can manage their weight through diet and exercise, the study found that Labrador owners who strictly controlled food intake and activity helped prevent obesity in their dogs—even in genetically predisposed ones.
40-60% of pet dogs are overweight or obese, similar to human obesity rates.
Labradors with the DENND1B gene had 8% more body fat than those without it.
US obesity rates exceed 42%, according to the Centers for Disease Control and Prevention (CDC).
Weight-loss drugs like Ozempic and Wegovy target brain pathways that regulate appetite.
Dr. Alyce McClellan, joint first author of the study, noted that while this research helps scientists understand how genes influence eating behavior, it doesn't immediately translate to weight-loss drugs.
"These genes are not immediately obvious targets for weight-loss drugs, because they control other key biological processes in the body that should not be interfered with," McClellan explained.
However, the study reinforces the importance of fundamental brain pathways in controlling appetite and body weight.
What's next
The discovery strengthens the case that obesity is not simply a matter of willpower, but a complex interaction between genetics and environment.
While drugs like Ozempic and Wegovy target hormones that regulate appetite, the study suggests that brain pathways controlling hunger signals may hold additional insights into why some people are more prone to weight gain.
For pet owners, researchers recommend strategies to manage a dog's food intake, including puzzle feeders and scattering food to slow eating and increase mental stimulation.
"Studying the dogs meant we had reason to focus on this particular gene, which has led to a big advance in understanding how our own brain controls our eating behavior and energy use," Raffan said.
As scientists continue to explore genetic influences on obesity, this study highlights that solutions may not be one-size-fits-all, but tailored to individual biology—whether human or canine.
The Source
This report is based on findings published in Science, with statements from University of Cambridge researchers and data from the Centers for Disease Control and Prevention (CDC).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dave Ramsey Prefers His Dog To Most People, But He's Clear On One Thing—You Don't Go '$14,000 In Debt To Put New Hips In A Labrador'
Dave Ramsey says he genuinely loves his dog more than most people. In a recent post on X, the personal finance expert shared, 'I've got a little Havanese bear dog, it's 12 pounds. I truly prefer this dog to most people, I really do.'Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Maximize saving for your retirement and cut down on taxes: . But Ramsey didn't stop there. He pointed out that many dog lovers let their emotions take over when it comes to their pets' medical care. 'We spend $8,000 to keep the dog alive while the dog is suffering, and it's not fair to the dog,' he said. 'Most of the time, this is about the person, not the dog.' Ramsey admitted he's faced this tough choice himself, having had to put dogs down. 'I've sat there and cried, sobbed while the vet puts one of them down. But that requires more courage than prolonging the dog's life and letting it suffer,' he said. The core of his message: love your dog, but don't let guilt or fear justify irresponsible spending. He suggested that how much you spend should depend on what you can reasonably afford. 'Do I go $14,000 in debt to put new hips into a Labrador retriever? No, you do not,' he emphasized. Trending: Invest where it hurts — and help millions heal:. His comments reflect a broader financial truth—tough decisions often arise when pets become seriously ill or injured, and the costs can be staggering. A recent article by MetLife (NYSE:MET) laid out just how expensive dog health issues can be: Intervertebral disc disease: up to $12,000 Bloat: $8,000+ Cancer treatments: $8,000+ Intestinal blockage surgery: up to $7,000 Hip dysplasia: up to $6,000 Cruciate ligament tear: $5,000+ Broken bones: $2,400 to $8,000 Poisoning or toxicity: up to $5,000 According to MetLife, some dog breeds are more prone to expensive issues than others. Cavalier King Charles spaniels, bulldogs, dachshunds and Great Danes, for instance, tend to have more health problems. Breeds like poodles, beagles, border collies and Havanese – – like Ramsey's own dog – tend to be healthier agrees with treating pets when it makes sense. 'If we can actually fix the animal, well, sure, we would spend some money on it,' he said. But he stressed that it should never come at the cost of financial ruin or prolonging a pet's suffering. 'They have a lifespan of 10, 12 years, maybe. So we outlive 10 or 12 of them if you live to be 70 years old,' he said. 'You kind of got to get that built into the system here and not put the poor animal through suffering because you're a big baby and you can't cry.' Read Next: Here's what Americans think you need to be considered Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Dave Ramsey Prefers His Dog To Most People, But He's Clear On One Thing—You Don't Go '$14,000 In Debt To Put New Hips In A Labrador' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
5 hours ago
- Miami Herald
Meth makes comeback in Minnesota in more dangerous and record ways
A subtle shift was happening among clients at the north Minneapolis community drop-in center. For years, people seeking substance abuse services at Anything Helps reported using just one drug of choice. Recently, staff noticed more and more users had expanded their appetite, preferring a combination of drugs at once versus 'picking a lane.' The polysubstance abuse among their regulars soon evolved almost exclusively to one pairing of drugs in the majority of their clients: fentanyl and methamphetamine. 'That's pretty new,' according to Brian Warden, the nonprofit's harm reduction director. 'That's something we traditionally see in cities like Denver, San Francisco or Seattle. That's not something we've really seen here.' To Warden, the change in the clientele's drug use pattern could stem from a number of reasons, including a correlation with a rise in homelessness in Minneapolis. But undoubtedly, he said, the phenomenon can be explained in part by the recent surge of methamphetamine in Minnesota. As the deadly fentanyl crisis demanded the state's attention post-pandemic, another was building with methamphetamine. The stimulant, long supreme in the underbelly of Minnesota's drug scene, is flooding the state - with a more dangerous dosage than meth of the past. 'The numbers are just a ridiculous amount of meth ... it just hasn't gotten enough publicity,' said Rafael Mattei, acting special agent in charge of the U.S. Drug Enforcement Administration's division over Minnesota. The meth surge in Minnesota came just as the street fentanyl crisis showed signs of easing. U.S. opioid overdose deaths plummeted 41% in 2024, according to the Centers for Disease Control and Prevention, and fatal overdoses of all kinds fell 27%. In Minnesota, preliminary data from the Minnesota Department of Health showed an 8% drop in overall overdose deaths from 2022 to 2023. But meth 'has never gone away,' Mattei said. No longer homemade in makeshift labs, meth is being churned out of Mexican super labs by cartels that cashed in on the lack of supply and cheaper production costs. And its price has plummeted, becoming a more lucrative option for dealers. Ken Sass, statewide drug and gang coordinator for the Minnesota Department of Public Safety, recalled a pound of meth costing $3,000 to $5,000 around 15 years ago, during his tenure as a federal drug agent. Now, he estimates, the price has fallen below $1,000. The drug makes its way to Minnesota most often by snaking up the Interstate 35 corridor to be sold in droves or continue into neighboring states. Last year, federal officials announced they had busted 'one of the largest and most prolific drug organizations' in Minnesota's history following the arrest of a Twin Cities man accused of helping push a historic amount of meth and other substances from Mexico. Federal prosecutors allege Clinton Ward made ties with two of Mexico's most notorious drug cartels and funneled the substance across the border via shipping containers, private vehicles and semitrailers before breaking the drug down into smaller quantities, then delivering it to Minnesota. The U.S. Attorney's Office charged Ward under the rare 'kingpin' statute, along with 14 others in the conspiracy case that led to the seizure of 1,600 pounds of methamphetamine, 4 kilograms of cocaine, 2 kilograms of fentanyl and 30,000 counterfeit fentanyl pills. Federal officials described the bust as a success for having disrupted a major pipeline of illegal drugs in Minnesota. Yet methamphetamine is continuing to pour into Minnesota with no sign of slowing down, data from the DEA indicates. Last year, the amount of methamphetamine seized by federal agents in Minnesota increased 142%, totaling 2,080 pounds, compared with the roughly 860 pounds of meth seized in 2023. The numbers do not include drugs seized by state, local or tribal law enforcement. Federal drug agents are on track to outpace the amount of meth seized last year. They've seen a 25% increase in the amount of meth seized from January to April 2025, compared with the same time last year. More readily available meth, Sass said, 'leads to more addiction and probably a broadening market as well.' And although meth may not be as lethal as fentanyl, the drug today poses its own dangers. The meth from Mexican super labs holds higher potency, resulting in a more dangerous and addictive concoction than the meth sold in the 1990s and early 2000s. After federal legislation in 2005 cracked down on the commercial sale of products containing precursor chemicals to make meth, such as pseudoephedrine in the decongestant Sudafed, cartels pursued the chemicals overseas and became bulk buyers. The product is then cut with other hazardous materials to bring maximum profit. Users deep in the throes of meth addiction can stay awake for days, leading to paranoia and hallucinations. A hallmark sign of meth addiction is wounds on a user's skin caused by incessant scratching. People who experience withdrawals may resort to theft, robbery or other crimes to obtain money for another hit. The elevated potency can only worsen symptoms, which carry ripple effects into communities. 'Their health, their mental health, their relationships, medical conditions that arise from addiction and all the personal problems that would come from [addiction] ... they relay that to the relationships with their family,' Sass said. In some cases, law enforcement and treatment providers are seeing fentanyl added to methamphetamine. Though the risk of dying from a meth overdose is much lower than that of fentanyl, which has a deadly dose that can fit on the tip of a pencil, the drug takes its toll 'little by little.' 'There is no accident here,' Warden said, saying of the adulteration of fentanyl with meth, 'I've never seen anything like that before.' Mattei likened the difference between the meth on the streets today compared with meth of the past as that of whiskey versus beer. 'They were making beer first,' Mattei said. 'Now the meth that's out there is kind of like higher-proof alcohol. So you need less to feel.' Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
